title: Prefrontal/amygdalar system determines stress coping behavior through 5-HT/GABA connection.
abstract: Coping is defined as the behavioral and physiological effort made to master stressful situations. The ability to cope with stress leads either to healthy or to pathogenic outcomes. The medial prefrontal cortex (mpFC) and amygdala are acknowledged as having a major role in stress-related behaviors, and mpFC has a critical role in the regulation of amygdala-mediated arousal in response to emotionally salient stimuli. Prefrontal cortical serotonin (5-hydroxytryptamine (5-HT)) is involved in corticolimbic circuitry, and GABA has a major role in amygdala functioning. Here, using mice, it was assessed whether amygdalar GABA regulation by prefrontal 5-HT is involved in processing stressful experiences and in determining coping outcomes. First (experiment 1), bilateral selective 5-HT depletion in mpFC of mice reduced GABA release induced by stress in basolateral amygdala (BLA) and passive coping in the Forced Swimming Test (FST) (experiment 2). Moreover, prefrontal-amygdala disconnection procedure that combined a selective unilateral 5-HT depletion of mpFC and infusion of an inhibitor of GABA synthesis into the contralateral BLA, thereby to disrupt prefrontal-amygdalar serial connectivity bilaterally, showed that disconnection selectively decreases immobility in the FST. These results point to prefrontal/amygdala connectivity mediated by 5-HT and GABA transmission as a critical neural mechanism in stress-induced behavior.
authors: Santa Lucia Foundation, Rome, Italy. diego.andolina@gmail.com
authors: Diego
authors: D
authors: Andolina
authors: Dario
authors: D
authors: Maran
authors: Alessandro
authors: A
authors: Valzania
authors: David
authors: D
authors: Conversi
authors: Stefano
authors: S
authors: Puglisi-Allegra
mesh_terms: D015116:5,7-Dihydroxytryptamine / Q000008:administration & dosage / Q000494:pharmacology; D000223:Adaptation, Psychological / Q000187:drug effects / Q000502:physiology*; D000501:Allylglycine / Q000008:administration & dosage / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D018756:GABA Antagonists / Q000494:pharmacology; D046353:Immobility Response, Tonic / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D008845:Microinjections; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D009638:Norepinephrine / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism*; D013315:Stress, Psychological / Q000378:metabolism / Q000503:physiopathology* / Q000523:psychology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D018756:GABA Antagonists; D000501:Allylglycine; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D004298:Dopamine; D009638:Norepinephrine
references: J Neurochem. 2005 Aug;94(3):672-9
references: 15992383
references: J Neurophysiol. 2004 Jul;92(1):1-9
references: 15212433
references: J Comp Neurol. 2008 May 20;508(3):458-72
references: 18335544
references: Synapse. 2009 Jan;63(1):82-5
references: 18932226
references: Neuropsychopharmacology. 2005 Dec;30(12):2205-15
references: 15886717
references: Nature. 1977 Apr 21;266(5604):730-2
references: 559941
references: Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5181-6
references: 17360372
references: Nat Neurosci. 2005 Mar;8(3):365-71
references: 15696163
references: Prog Brain Res. 1996;107:3-6
references: 8782510
references: Mol Psychiatry. 2002;7 Suppl 1:S71-80
references: 11986998
references: Cereb Cortex. 2004 Mar;14(3):281-99
references: 14754868
references: Eur J Neurosci. 2005 Jan;21(2):441-54
references: 15673443
references: Neuroscience. 1995 Jan;64(2):477-505
references: 7700534
references: Brain Behav Evol. 2007;70(4):218-26
references: 17914253
references: J Neurosci. 2004 Apr 7;24(14):3471-9
references: 15071094
references: Brain Res Bull. 2000 Jun;52(3):171-82
references: 10822158
references: J Neurosci Methods. 2004 Dec 30;140(1-2):169-81
references: 15589347
references: Trends Pharmacol Sci. 2005 Jan;26(1):36-43
references: 15629203
references: Brain Res. 1991 Feb 22;542(1):91-6
references: 2054663
references: Neuron. 2008 Feb 7;57(3):432-41
references: 18255035
references: Neuroreport. 2000 Apr 27;11(6):1361-4
references: 10817622
references: J Neurosci. 1988 Jul;8(7):2517-29
references: 2854842
references: Nat Neurosci. 2005 Jun;8(6):828-34
references: 15880108
references: Brain Res. 2009 Feb 23;1256:61-8
references: 19124010
references: Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9870-5
references: 17535909
references: Pharmacol Biochem Behav. 2005 Mar;80(3):463-70
references: 15740789
references: Behav Brain Res. 2011 Feb 2;217(1):155-64
references: 20974185
references: J Neurosci. 2003 Sep 24;23(25):8800-7
references: 14507980
references: Brain Res. 2010 Oct 8;1355:52-60
references: 20727864
references: Cereb Cortex. 2007 Feb;17(2):251-60
references: 16495432
references: Cereb Cortex. 2009 Nov;19(11):2499-507
references: 19321655
references: Synapse. 2004 Jan;51(1):32-58
references: 14579424
references: Behav Neurosci. 1983 Jun;97(3):452-61
references: 6683562
references: Neurotox Res. 2002 Aug-Sep;4(5-6):409-419
references: 12754155
references: Eur J Neurosci. 2000 Jan;12(1):367-75
references: 10651892
references: Nat Neurosci. 2005 Jan;8(1):20-1
references: 15592465
references: Synapse. 2002 Aug;45(2):86-94
references: 12112401
references: J Comp Neurol. 2005 Nov 14;492(2):145-77
references: 16196030
references: Annu Rev Clin Psychol. 2007;3:377-401
references: 17716061
references: J Neurosci. 2007 Jan 17;27(3):684-91
references: 17234600
references: Neuropsychopharmacology. 2011 Mar;36(4):793-804
references: 21160468
references: Neuropsychopharmacology. 2008 Jul;33(8):1929-41
references: 17957216
references: Pharmacol Rev. 1995 Mar;47(1):133-78
references: 7784478
references: Psychopharmacology (Berl). 2002 Nov;164(2):138-43
references: 12404075
references: Ann N Y Acad Sci. 2001 Mar;933:265-77
references: 12000027
references: Trends Pharmacol Sci. 2007 Dec;28(12):629-36
references: 17996955
references: Neurosci Biobehav Rev. 2012 Jan;36(1):79-89
references: 21565217
references: Neuropsychopharmacology. 2005 Feb;30(2):223-30
references: 15536493
references: Brain Res. 2010 Feb 16;1314:29-37
references: 19800322
references: Biol Psychiatry. 2010 Mar 1;67(5):397-8
references: 20159143
references: Ann N Y Acad Sci. 1999 Jun 29;877:614-37
references: 10415674
references: J Neurosci. 2005 Aug 10;25(32):7429-37
references: 16093394
references: Physiol Rev. 2007 Jul;87(3):873-904
references: 17615391
references: J Neurophysiol. 1999 Jul;82(1):69-85
references: 10400936
references: Int J Neuropsychopharmacol. 2009 Sep;12(8):1067-79
references: 19664307
references: J Neurosci. 2005 Sep 21;25(38):8725-34
references: 16177042
references: Neuroscience. 2005;132(4):943-53
references: 15857700